Information  X 
Enter a valid email address

Summit Corporation (SUMM)

  Print      Mail a friend

Tuesday 23 October, 2007

Summit Corporation

Clinical Update

Summit Corporation PLC
23 October 2007

Summit Corporation plc
('Summit' or 'the Company')


Oxford, UK, 23 October 2007 - Summit Corporation plc (AIM: SUMM) announces the
commencement of a Phase I clinical trial of SMT D002 for the treatment of
seborrhoea (excessive sebum production), a symptom of Parkinson's disease and
the primary cause of acne.

The recruitment of 18 healthy volunteers for the trial is complete with dosing
now underway; treatment is expected to last for five weeks.  The study will
examine the effects of repeat oral doses of SMT D002 on sebum excretion rates
and thereby add to results of an earlier double-blind Phase I study in healthy
volunteers using a single oral dose that showed up to a 70% reduction in sebum
excretion.  Summit expects to report the results from this new study during Q1

In addition to treating seborrhoea in Parkinson's disease, Summit believes that
SMT D002 also has potential use in other therapeutic areas, particularly acne
where a reduction in sebum levels would be beneficial.  SMT D002 would represent
a brand new treatment for acne and future studies planned under its programme in
both areas will assess the potential of SMT D002 in a topical formulation as
well as oral, in order to establish proof of concept and to create an attractive
commercial offering for out-licensing.

SMT D002 has been developed using Summit's drug reprofiling expertise whereby
the Company has identified these new indications in Parkinson's disease and acne
for a marketed, off-patent small molecule drug that has a long, established
history of safe use.  The Company has a strong patent position to protect the
use of SMT D002 in these new indications.

Steven Lee, CEO of Summit plc, commented 'In March 2007, Summit acquired two
early clinical programmes that target two of the distressing symptoms associated
with Parkinson's disease - sialorrhoea and seborrhoea - when it acquired
DanioLabs.  Our strategy with these programmes is to advance them to demonstrate
clinical proof of concept, thereby adding value and improving their commercial
attractiveness to potential licensees. The start of this new clinical trial in
seborrhoea, in addition to progress we have made with our drug candidate to
treat sialorrhoea (excessive drooling), which is expected to enter a Phase I/IIa
clinical trial by the end of 2007, is indicative of the solid progress being
made in our enhanced drug discovery and development pipeline towards our
commercial objectives.'

                                    - ENDS -

For more information, please contact:
Summit plc
Steven Lee, PhD, Chief Executive Officer                Tel: +44 (0)1235 443951
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations

Citigate Dewe Rogerson
Mark Swallow / David Dible / Yvonne Alexander           Tel: +44 (0)207 638 9571

Evolution Securities
Tim Worlledge / Bobbie Hilliam / Neil Elliot            Tel: +44 (0)207 071 4300

About Summit plc

Summit plc is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced carbohydrate chemistry and drug screening (chemical
genomics) technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.

Summit plc has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.

Summit plc's in-house drug development capabilities combine world-class
expertise in both carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: SUMM

Further information about the company is available at

This document contains 'forward-looking statements' within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as 'anticipates', 'intends', 'plans',
'seeks', 'believes', 'estimates', 'expects' and similar references to future
periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory

                      This information is provided by RNS
            The company news service from the London Stock Exchange